Cytokine-Like 1 Regulates Cardiac Fibrosis via Modulation of TGF-beta Signalingopen access
- Authors
- Kim, Jooyeon; Kim, Jihwa; Lee, Seung Hee; Kepreotis, Sacha V.; Yoo, Jimeen; Chun, Jang-Soo; Hajjar, Roger J.; Jeong, Dongtak; Park, Woo Jin
- Issue Date
- Nov-2016
- Publisher
- PUBLIC LIBRARY SCIENCE
- Citation
- PLOS ONE, v.11, no.11, pp 1 - 15
- Pages
- 15
- Indexed
- SCIE
SCOPUS
- Journal Title
- PLOS ONE
- Volume
- 11
- Number
- 11
- Start Page
- 1
- End Page
- 15
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/12211
- DOI
- 10.1371/journal.pone.0166480
- ISSN
- 1932-6203
- Abstract
- Cytokine-like 1 (Cytl1) is a secreted protein that is involved in diverse biological processes. A comparative modeling study indicated that Cytl1 is structurally and functionally similar to monocyte chemoattractant protein 1 (MCP-1). As MCP-1 plays an important role in cardiac fibrosis (CF) and heart failure (HF), we investigated the role of Cytl1 in a mouse model of CF and HF. Cytl1 was upregulated in the failing mouse heart. Pressure overload-induced CF was significantly attenuated in cytl1 knock-out (KO) mice compared to that from wild-type (WT) mice. By contrast, adeno-associated virus (AAV)-mediated overexpression of cytl1 alone led to the development of CF in vivo. The endothelial-mesenchymal transition (EndMT) and the transdifferentiation of fibroblasts (FBs) to myofibroblasts (MFBs) have been suggested to contribute considerably to CF. Adenovirus-mediated overexpression of cytl1 was sufficient to induce these two critical CF-related processes in vitro, which were completely abrogated by co-treatment with SB-431542, an antagonist of TGF-beta receptor 1. Cytl1 induced the expression of TGF-beta 2 both in vivo and in vitro. Antagonizing the receptor for MCP-1, C-C chemokine receptor type 2 (CCR2), with CAS 445479-97-0 did not block the pro-fibrotic activity of Cytl1 in vitro. Collectively, our data suggest that Cytl1 plays an essential role in CF likely through activating the TGF-beta-SMAD signaling pathway. Although the receptor for Cyt1l remains to be identified, Cytl1 provides a novel platform for the development of anti-CF therapies.
- Files in This Item
-
- Appears in
Collections - COLLEGE OF SCIENCE AND CONVERGENCE TECHNOLOGY > ERICA 의약생명과학과 > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.